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Abstract: Obsessional states show an average point prevalence of 1%–3% and a lifetime 
prevalence of  2%–2.5%. Most treatment-seeking patients with obsessions continue to experience 
significant symptoms after 2 years of prospective follow-up. A significant burden of impairment, 
distress, and comorbidity characterize the course of the illness, leading to an increased need 
for a better understanding of the nature and management of this condition. This review aims to 
give a representation of the current pharmacological and psychotherapeutic strategies used in 
the treatment of obsessive-compulsive disorder. Antidepressants (clomipramine and selective 
serotonin reuptake inhibitors) are generally the first-line choice used to handle obsessional states, 
showing good response rates and long-term positive outcomes. About 40% of patients fail to 
respond to selective serotonin reuptake inhibitors. So far, additional pharmacological treatment 
strategies have been shown to be effective, ie, administration of high doses of selective serotonin 
reuptake inhibitors, as well as combinations of different drugs, such as dopamine antagonists, 
are considered efficacious and well tolerated strategies in terms of symptom remission and side 
effects. Psychotherapy also plays an important role in the management of obsessive-compulsive 
disorder, being effective for a wide range of symptoms, and many studies have assessed its 
long-term efficacy, especially when added to appropriate pharmacotherapy. In this paper, we 
also give a description of the clinical and psychological features likely to characterize patients 
refractory to treatment for this illness, with the aim of highlighting the need for greater attention 
to more patient-oriented management of the disease.
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Introduction
Obsessions are defined as “intrusive, repetitive thoughts, images or impulses that are 
unacceptable and/or unwanted and rise to subjective resistance; the necessary and 
sufficient conditions are intrusiveness, internal attribution and difficulty of control.”1 
In addition to their intrusive and disturbing quality, obsessive concerns have tradition-
ally been conceptualized as ego-dystonic (alien to the self). Individuals with obsessive 
disorder typically engage in repetitive compulsive behaviors or mental processes that 
cause distress or interfere with functioning, and often avoid those things or situa-
tions that trigger their obsessive and/or compulsive behaviors, so avoidance behavior 
becomes a central feature of the disorder.2
Although the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV) classifies obsessive-compulsive disorder (OCD) as an anxiety 
disorder, some clinicians consider it to be a spectrum of related disorders, which 
includes the somatoform disorders (body dysmorphic disorder and hypochondriasis), 
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impulse-control disorder, and tic disorders. Anxious and 
phobic manifestations have been included within the OCD 
spectrum, but there is an increasing need among psychiatrists 
for a clear definition of the clinical features and dimensions 
of symptoms.3
Epidemiology
Epidemiological surveys of obsessional states show 
an average point prevalence of 1%–3% and a lifetime 
prevalence of 2%–2.5%, with a predominance of female 
cases.4 Most treatment-seeking patients with obsessions 
continue to experience significant symptoms after 2 years of 
prospective follow-up. Earlier age at onset, greater severity 
of symptoms, being older, and male gender seem to be 
associated with a decreased likelihood of full or partial 
remission. A significant burden of impairment, distress, and 
comorbidity characterize the course of the illness.5 Suicidal 
attempts are quite frequent in obsessive patients, thus giving 
a clear indication of unmet need and the necessity to increase 
the level of awareness about the nature and management of 
this condition.6
Pathogenesis
A growing body of evidence supports a role for increased 
midbrain/basal ganglia dopaminergic neurotransmission, 
which attenuates the ability of the frontal cortex to sup-
press affective responses generated in the amygdala.7 Many 
candidate genes have been analyzed to understand the 
pathophysiological basis of obsessions, with serotonergic, 
dopaminergic, and glutamatergic genes being the most 
often implicated.8 More recently, a role for glutamatergic 
hyperactivity has been hypothesized, secondary to a lack of 
serotoninergic inhibition of the orbitofrontal, thalamic, and 
striatal areas.9
Current treatments
Many studies have been performed to understand better and 
improve the therapeutic management of phobic-obsessive 
disorders. Here we present a review of the treatment strate-
gies proposed so far, with the aim of giving practical and 
comprehensive information on this topic.
Serotonin reuptake inhibition
Clomipramine is a tricyclic antidepressant and acts by inhibit-
ing reuptake of norepinephrine and serotonin, but serotonin 
inhibition is more pronounced. It is clearly recognized that 
clomipramine has a unique antiobsessional effect as a result 
of its potent serotonin reuptake inhibition, and this agent 
has also helped to clarify biological aspects involved in the 
disorder.10,11 Several studies have demonstrated that clomip-
ramine 150–300 mg/day for 8–16 weeks causes an average 
decrease of 25%–30% in Y-BOCS scores (a widely used 
measure administered by clinicians to assesses the severity of 
obsessive-compulsive symptoms over the   previous week).12,13 
The efficacy of clomipramine compared with selective 
serotonin reuptake inhibitors (SSRI) has been reviewed 
thoroughly, providing evidence of equivalent antiobsessional 
efficacy, with the SSRI nevertheless being better tolerated 
and having a more favorable side effect profile, so being 
preferable as first-line treatment.14–16
Selective serotonin reuptake inhibition
Paroxetine
Most of the active principals within this pharmacological 
class have been investigated in the treatment of obsessive 
disorder and phobic behaviors, and been shown to be effi-
cacious both in the acute and maintenance phases, and well 
tolerated in terms of side effects.20,33,46,54 Several studies have 
investigated paroxetine in the acute treatment of obsessions. 
Clinically significant improvements are evident at doses of 
20–60 mg/day with respect to depressive symptoms, anxiety, 
and overall functioning. Moreover, paroxetine shows a wide 
spectrum of antianxiety effects and can be recommended as 
first-line therapy in treating comorbidities.17,18 Paroxetine 
was found to reduce symptoms of avoidance associated 
with phobic-related behaviors and to improve patient qual-
ity of life significantly.19 Depressive symptoms, which 
often co-occur, were shown to ameliorate during paroxetine 
treatment, and such improvement seems to be the result of 
increased social interaction subsequent to a reduction in fear 
and avoidance.20
The long-term safety and efficacy of paroxetine, as 
well as its impact on prevention of relapse of obsessive 
symptoms, have been assessed, showing paroxetine to be 
effective and generally well tolerated. Doses of at least 
40 mg/day are necessary to obtain a good outcome. In 
addition, long-term treatment can sustain the clinical 
improvement obtained with short-term treatment, and can 
prevent recurrence of symptoms without any increase in 
adverse events.
Significant reduction in disease severity and improvement 
in phobic states were maintained with continued treatment 
using paroxetine (up to 36 weeks), showing a reduced risk of 
relapse, allowing patients to improve their capacity to rebuild 
social and professional relationships, and leading to a more 
productive and satisfying life.21
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Fluvoxamine
The complex pattern of activity of fluvoxamine may account 
for its efficacy in the treatment of obsessional states, although 
its pharmacokinetic profile and pattern of side effects may 
hinder rapid dose escalation. Controlled studies conducted 
over 6–12 weeks showed a good response to fluvoxamine 
(dose range 100–300 mg/day).22,23 The majority of studies 
were conducted with clomipramine as the comparator, and 
the two drugs were shown to be equally effective, with 
clomipramine being less tolerated due to adverse effects.24,25 
Social anxiety, avoidance, and phobic symptoms were 
shown to decrease after 6–8 weeks of fluvoxamine treat-
ment, and continued to improve by week 12.26 Long-term 
treatment (40 weeks) with fluvoxamine in the dose range of 
100–300 mg/day was found to correlate with improvement in 
psychosocial skills, together with improvement of   obsessive 
symptoms.27
Escitalopram
Escitalopram shows high serotonin reuptake selectivity, favor-
able pharmacokinetics, and comparatively good tolerability, 
suggesting a potential role in the treatment of obsessional 
states.28 Clinical improvement appears at a dose of 20 mg/day, 
and escitalopram seems to produce significant benefits in 
overall disease severity as well as global improvement.29,30 
Data from a placebo-controlled study showed escitalopram to 
have good efficacy across several obsessive symptom dimen-
sions, including contamination, symmetry, somatic obses-
sions, cleaning, checking, and ordering compulsions.31
Short-term treatment with escitalopram was found to pro-
duce better results than paroxetine in terms of improvement 
in different phobic symptom dimensions, including social 
interaction, fears, and assertiveness. Three different doses 
of the drug (5, 10, and 20 mg/day) were compared with a 
fixed dose of paroxetine (20 mg/day) during a 12-week trial, 
with escitalopram showing both greater efficacy and better 
tolerability.32
Escitalopram was shown to be effective in preventing 
relapse and to be safe and generally well tolerated for the 
long-term treatment of obsessive states. In a 24-week study, 
escitalopram 10 mg and 20 mg were both effective for all 
primary and secondary outcome measures in preventing 
relapse, and escitalopram’s antiobsessional effects, obtained 
with short-term treatment, was maintained throughout the 
study period.33
A 24-week trial of fixed doses of escitalopram (5, 10, and 
20 mg/day) demonstrated its long-term efficacy across various 
symptom dimensions in a group of patients   suffering from 
phobic avoidance-related states.34 A significant   reduction 
in relapses was shown with flexible doses of escitalopram 
(10–20 mg/day) compared with placebo (22% versus 50%) in 
a 24-week relapse prevention study,   suggesting that a much 
longer period of treatment may be necessary to achieve a 
long-lasting positive outcome.35
Fluoxetine
Fluoxetine has been investigated since 1985, and has been 
shown to be effective in obsessive disorders at the dose range 
of 40–60 mg daily.36–38 The effects of fluoxetine on different 
clinical subtypes of OCD have been investigated, showing a 
significant decrease in symptoms, with greater efficacy for 
obsessive thoughts and washing compulsions,39 as well as 
improvement in psychosocial functioning and quality of life.40 
As regards management of phobic symptoms, fluoxetine was 
shown to be as efficacious as placebo for short-term treatment 
and in a 24-week maintenance phase both as monotherapy 
and in association with comprehensive cognitive behavioral 
therapy.41–43 Fluoxetine was shown to be efficacious and safe 
for preventing relapse of obsessive disorders in patients who 
responded to its short-term administration. Low overall rates 
of relapse were evident at the maintenance dose of 40 mg/day, 
but the 60 mg/day dose seemed to provide greater protection. 
It was found to have a good safety profile, and adverse effects 
rarely led to discontinuation of treatment.44
Citalopram
Citalopram has been investigated for its efficacy in the 
treatment of obsessive disorder, with the highest response 
rate found at 60 mg/day, together with good tolerability.45 It 
was shown to improve psychosocial functioning, mental and 
physical health-related quality of life, and delusional as well 
as depressive symptoms, together with a decrease in obses-
sional preoccupation, repetitive behavior, and distress.46,47 
Its efficacy has also been demonstrated in the short-term 
treatment of phobic anxiety and avoidance behavior. In 
8–12-week trials, citalopram at dosages of 20–60 mg/day 
seemed to produce a positive clinical outcome and to be well 
tolerated, with 75%–86% of subjects being deemed respond-
ers, and no withdrawals due to side effects.48,49   Citalopram 
appears to be efficacious in patients with refractory obsessive 
disorder who do not respond to other treatments. Moreover, 
it seems to be a useful strategy when other psychiatric 
conditions coexist together with obsessions.50 Long-term 
treatment with citalopram was investigated in a large 
sample of acute patients suffering from phobic avoidance 
and anxiety-related symptoms of arousal, and citalopram 
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20–30 mg/day appeared to be the most effective dosage in 
terms of clinical improvement.51
Sertraline
Sertraline has been evaluated for its efficacy and safety in 
obsessional states at dosages of 50–200 mg/day, with positive 
results.52 A faster response is achieved with rapid titration of 
sertraline up to 200 mg/day. The faster the achievement of the 
full dose, the earlier the relief of OCD symptoms, especially 
when a rapid response is needed without undue delay. With 
respect to tolerability, the number of side effects, as well as 
discontinuation rates, seems to be comparable between fast 
and slow titration strategies, suggesting that the dosage per se, 
and not the time to full dose achievement, is important in 
determining tolerability.53 A comparative study investigating 
the efficacy of sertraline versus cognitive behavioral therapy 
in the short-term treatment of obsessive disorder showed 
comparable positive outcomes for both treatment in managing 
symptoms of anxiety and depression, together with improved 
quality of life.54 Sertraline showed significant efficacy, com-
pared with placebo, in the management of phobic-related 
states, with greater symptom reduction across the domains of 
anxiety/fearfulness, physiological symptoms, and behavioral 
avoidance.55 Clinical improvements in obsessive disorders and 
phobic behaviors have been achieved by long-term therapy 
with sertraline, and with a good side effect profile. A 20-week 
trial with sertraline 50–200 mg/day produced significant 
improvement, both in work functioning and in social skills, 
together with high tolerability.56 Relapse prevention studies 
have shown that sertraline significantly ameliorates symptoms 
of anxiety and avoidance behavior after 24 weeks of treatment. 
The avoidance dimension was the last to be improved, suggest-
ing that this clinical outcome may require longer-term therapy 
to overcome well established behavioral patterns.57 Sertraline 
showed lower relapse rates, a better clinical response, and 
overall improvement in quality of life.58,59 High-dose sertra-
line (250–400 mg/day) has been assessed in the treatment of 
patients who have failed to respond to standard doses, showing 
significant symptom improvement and an adverse event rate 
similar to that seen at a dosage of 200 mg/day.60
Selective noradrenergic-serotonin 
reuptake inhibition
Selective noradrenergic-serotonin reuptake inhibitors (SNRI) 
combine the actions of SSRI with noradrenergic reuptake 
inhibitors, have a robust effect on serotonin, and do not block 
α1-adrenergic, cholinergic, or histaminergic receptors, thus 
showing better tolerability.
venlafaxine
Venlafaxine has been found to have efficacy equivalent to 
that of clomipramine in short-term treatment, but with a more 
favorable safety profile.61 The majority of venlafaxine trials have 
demonstrated the efficacy of this compound in short-term and 
medium-term trials and in both treatment-naïve and treatment-
resistant obsessive patients. In two double-blind, active com-
parative studies, venlafaxine was shown to be more effective 
than paroxetine and clomipramine. Moreover, venlafaxine was 
shown to be particularly effective in patients who previously did 
not respond to SSRIs, and was well tolerated.62,63 An appropriate 
dosage of venlafaxine in the treatment of obsessional states is 
usually in the range of 150–300 mg/day, although higher doses 
may sometimes be required. A response may be observed as 
early as four weeks after beginning treatment, but continued 
improvement may be noted for up to about 10 weeks.64
Flexible  doses  of  venlafaxine  extended-release 
(75–225 mg/day) in the short term produced a significantly 
greater clinical improvement than placebo in managing 
phobic-related states, together with a good side effect profile. 
Most of the adverse events reported were mild to moderate 
in severity, and were similar to previous data from major 
depression and general anxiety disorder studies.65,66 The 
long-term efficacy and safety of venlafaxine extended-release 
at different dosages (75 mg/day and 150–225 mg/day) was 
assessed in a 6-month trial, showing comparable response 
and remission rates for both lower and higher doses.67
Duloxetine
Despite growing evidence of good efficacy for duloxetine 
in the treatment of anxiety disorders, there is a relative lack 
of data demonstrating its potential efficacy in obsessional 
states. There are some case reports of obsessive-compulsive 
patients with comorbid mood or anxiety disorders treated 
with serotonin reuptake inhibitors at adequate doses for at 
least 12 weeks and showing a partial response or no response, 
who were switched to duloxetine up to 120 mg/day with 
significant clinical improvement, pointing to a role for dulox-
etine in patients with treatment-resistant OCD.68
Antipsychotics
Although the effectiveness of SSRI has been well established 
in the treatment of obsessive disorders, about 40% of patients 
fail to respond to these agents, with only a minority expe-
riencing full remission of symptoms.69,70 For such patients, 
additional pharmacological strategies, such as higher doses 
of SSRI, as well as combination treatment with dopamine 
antagonists, have been investigated in several studies.71,72
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Dopamine antagonists have been shown to be the most 
effective agents for an augmentation strategy, with the 
atypical antipsychotics being better tolerated than traditional 
neuroleptics.73 The synergistic action of 5-HT2A receptor 
blockade by atypical agents, with the simultaneous inhibi-
tion of 5-HT uptake by SSRI, leads to greater therapeutic 
efficacy. Given the similar clinical efficacy of the SSRI in 
obsessional states, the variability in response could lie in their 
pharmacological effects on the 5-HT transporter, as well as 
on norepinephrine and dopamine transporters. These subtle 
differences between the SSRI in their 5-HT, norepinephrine, 
and dopamine transporter affinities might account for their 
different therapeutic effects when used in combination with 
various antipsychotics as an augmentation strategy.74 To date, 
there have been a number of studies conducted using dif-
ferent atypical compounds in order to understand better the 
therapeutic value of augmentation strategies, their convenient 
use, and their safety in obsessional states.
Risperidone
Addon risperidone therapy in patients with refractory obses-
sive symptoms has been studied by many investigators.75–77 
In a comparative study of risperidone 1 mg/day and halo-
peridol 2 mg/day, the atypical antipsychotic was found 
to improve obsessive symptoms, with a better side effect 
profile. In fact, in this study, none of the risperidone-treated 
subjects discontinued treatment because of adverse events, 
although its potential long-term effects were not considered.78 
  Risperidone 1–3 mg/day was found to be as efficacious and 
well tolerated as olanzapine 2.5 mg/day in patients failing 
to respond to the maximum tolerated daily dose of SSRI for 
at least 12 weeks. Both treatment groups showed a marked 
and significant improvement in obsessions and compulsions 
over the eight-week augmentation period, with the same 
response rates across time. Tolerability was comparable 
between the treatment groups, and differences only emerged 
when considering single adverse events, and showed that 
risperidone was more likely to be associated with akathisia 
and amenorrhea.79
Aripiprazole
Aripiprazole is a partial agonist at dopamine D2 and 5-HT1A 
receptors, and also acts as a 5-HT2A receptor antagonist. These 
dopamine-5-HT stabilizing properties might be of therapeutic 
value in obsessive disorders. There have been two case reports 
demonstrating the effectiveness of augmentation using arip-
iprazole 20 mg/day for severe obsessive symptoms, showing 
a significant clinical improvement at 6–12 weeks, together 
with long-lasting therapeutic effects.80 In another case report 
of a refractory obsessive patient (previously treated with high 
doses of clomipramine and sertraline, augmented with clon-
azepam, low doses of risperidone, and then olanzapine, with 
no beneficial effects), long-term improvement was evident 
with the addition of aripiprazole 7.5 mg/day.81
Olanzapine
Case reports and augmentation trials have suggested a role 
for olanzapine in the treatment of refractory obsessive 
disorders.82,83 An augmentation strategy using olanzapine at 
a low dose of 5 mg/day was assessed in patients refractory to 
a high dosage of fluvoxamine (300 mg/day) and in obsessive 
patients with an associated schizotypal personality disorder. 
At the endpoint, 43.5% of patients experienced significant 
symptom improvement; full response was achieved after 
2 months, with no discontinuations, despite a 39.1% weight 
gain among responders. Good tolerability was evident in both 
groups, with mild to moderate side effects.84 Olanzapine 
was found to induce greater symptom improvement during 
short-term treatment of refractory obsessive symptoms 
at the higher dose of 20 mg/day, with ongoing good 
tolerability.85
Quetiapine
Open studies and case reports have evaluated the efficacy 
of quetiapine as addon therapy in obsessional states.86,87 
In OCD patients refractory to at least two SSRI trials, 
quetiapine 200 mg/day was shown to be significantly more 
efficacious than SSRI monotherapy in reducing obsessive 
symptoms, with 40% of patients rated as responders. The 
response appeared to occur relatively rapidly and seemed to 
be especially promising in patients with severe obsession.88 
Another placebo-controlled study evaluated the efficacy of 
quetiapine in addition to citalopram in treatment-naïve obses-
sive patients. This trial was the first to assess the efficacy of 
quetiapine as addon medication to SSRI in nonrefractory 
patients, showing good primary outcome rates, with 69% of 
patients responding positively.89
A pooled study of all available placebo-controlled 
quetiapine addon trials was performed to assess treatment 
outcomes in a large sample of obsessive patients and to 
evaluate the impact of type and dose of SSRI required for 
efficacy. In a sample of 102 patients, the investigators found a 
significantly superior response in the quetiapine addon group 
compared with the placebo group. The best response was 
achieved with the combination of clomipramine, fluoxetine, 
and fluvoxamine.74
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Psychotherapy
Behavioral and cognitive therapies have been found to be 
effective in the treatment of obsessive disorder in several 
studies.90,91 In an effort to maximize the treatment effect in 
clinical practice, cognitive behavioral therapy is frequently 
combined with antidepressant therapy. A review of controlled 
trials and a meta-analysis that involved cognitive and/or 
behavioral treatment for obsessional states confirmed that 
both exposure and response prevention and cognitive therapy 
are effective methods for the treatment of obsessions and 
compulsions in children, adolescents, and adults.92
Both psychotherapy and medication have some disad-
vantages when considered separately. Many patients show 
poor motivation and adherence with psychotherapy as well as 
drug treatment. In clinical trials, up to 25% of patients refuse 
to engage in behavioral therapy, 13%–17% discontinue it 
prematurely,93 and 10%–30% of patients fail to respond.94
Biondi and Picardi assessed the long-term effectiveness 
of integrated treatment (medication plus cognitive behav-
ioral psychotherapy) compared with medication alone in 
20 consecutive patients with OCD who achieved remission 
or marked improvement after treatment with clomipramine 
or SSRI. Eight of 10 patients treated with medication alone 
relapsed versus one relapse in the integrated treatment 
group. It thus seems that an appropriate combination of 
psychotherapy and medication might be more effective than 
either treatment alone on the long-term course of the disease. 
Starting medication before psychotherapy and gradually 
discontinuing it before psychotherapy ends appears to be 
the best strategy, because medication might facilitate subse-
quent engagement of the patient in psychotherapy and help 
to increase self-efficacy.95
O’Connor et al compared the outcomes of therapy in 
four comparable groups of obsessive patients receiving four 
different treatments, ie, standardized medication only, pla-
cebo only, cognitive behavioral therapy only, and cognitive 
behavioral therapy following individualized medication. 
The results showed that all the active treatments improved 
the symptomatology, with a more specific antiobsessional 
effect of cognitive behavioral therapy than medication only. 
The groups receiving cognitive behavioral therapy had 
a significant decrease in obsessional doubts, anticipated 
consequences, self-efficacy in resisting ritual behavior, and 
degree of conviction in the need to perform the ritual, thus 
resulting in better cognition.96
Cognitive behavioral therapy, involving cognitive restruc-
turing and exposure to feared and avoided situations, has 
been found to be an efficacious therapy for   obsession-related 
phobic behaviors.42,97,98 The core of psychotherapy focuses 
on the distorted perceptions and beliefs which usually trig-
ger physical, behavioral, and cognitive symptoms producing 
discomfort, reinforcing a negative self-image, and increasing 
avoidant attitudes. Cognitive behavioral therapy seems to 
work in both the acute and maintenance phases of treatment. 
Its effects on durability of gains after discontinuation have 
been assessed in responders to either phenelzine or group 
cognitive behavioral therapy, the latter being more likely to 
maintain a response after the end of treatment.99
The same results were obtained in another trial showing 
combined treatment with cognitive behavioral group therapy 
and phenelzine to exert a truly additive and synergistic effect 
in the management of phobic symptoms.100 Combination 
therapy seems to be a useful strategy to manage both the 
clinical and social aspects of obsessive and phobic behaviors 
because it alleviates acute disturbing symptoms and enables 
patients to develop better self-awareness.
Treatment of refractory  
obsessive-compulsive disorder
Up to 40%–60% of patients with OCD do not respond to 
standard treatments, and develop a significant burden of 
disability and mordibity.101 Patients often express poor 
motivation or adherence towards both psychotherapy, 
with 25% refusing behavioral therapy,102,103 13%–17% 
discontinuing it prematurely,90–93 and 10%–30% showing an 
unsatisfactory response,94,103 with lack of motivation and poor 
compliance. Up to 20% of patients do not want to take drugs 
and 20%–25% stop medication prematurely.90–93 Moreover, 
37%–63% of patients in clinical trials do not respond to 
treatment.93 Follow-up studies have highlighted that discon-
tinuing medication leads to symptom exacerbation or relapse 
in 32%–89% of patients, even after long-term treatment and 
drug-tapering, and there is often a high risk of resistance to 
the drug used previously.104,105
Understanding the reason for early treatment interruption 
is an important step in identifying more effective therapeutic 
strategies. Thus, clarifying which factors are linked with 
noncompliance could enable the clinician to recognize the 
treatment option which best suits a particular patient and 
provide the greatest chance of compliance. A study by Diniz 
et al was performed to investigate the clinical correlates of 
early treatment discontinuation among OCD patients. Their 
major finding was that anxiety and somatization disorders 
were closely related to treatment discontinuation in their 
group of patients, who were treated only with SSRI. These 
authors argued that this could be connected with the initial 
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worsening of anxiety symptoms induced by SSRI medication 
which might push more vulnerable patients to early cessation 
of medication. They also observed better outcomes, in terms 
of compliance, with an increased frequency of consultations 
in the initial phase of their study.106
Both psychotherapy and medication differ in their 
strengths and weaknesses, thus it seems that a proper com-
bination of the two might be more appropriate and effective 
than either treatment alone.95 In many trials, combining the 
two strategies has been found to be more useful and clinically 
superior to medication or psychotherapy alone.11,107 Sapana 
et al performed an interesting study exploring treatment 
preferences in OCD patients, and showed that combined 
therapy (psychotherapy plus medication) appears to be the 
most preferred choice overall. There are several factors that 
may influence the treatment choices, ie, past positive or 
negative experiences, complexity of the procedure, patient 
attitudes, and self-education.108 It has emerged from several 
studies that discussing treatment preferences improves the 
therapeutic alliance and facilitates better uptake of treatment 
recommendations.109,110 Important areas to discuss include 
past treatment experiences, beliefs, or concerns about medica-
tions/psychotherapy, and practical issues, such as duration of 
therapy, side effects, and access to trained OCD providers.
Many factors have been linked with poor response to 
treatment, ie, sexual or religious obsessions,111 hoarding,112 
poor insight,113 psychiatric comorbidity,114 and early onset 
of the disease.115 The sexual and religious dimensions have 
been found to be an important issue in terms of treatment 
response. Some authors have shown a link between sexual 
and religious obsessive-compulsive symptoms and higher 
rates of refractoriness and less favorable outcomes, both in 
pharmacological and psychotherapy trials.111–116 Social and 
cultural aspects should not be underestimated in this regard. 
Social contexts and cultural background play an important 
role in establishing values and beliefs. Thus, some sexual 
and religious thoughts can be almost unbearable for patients 
with a strong inner moral structure, and their obsessive 
quality can be experienced as an expression of their high 
moral values rather than as mental distress. This could lead 
to development of feelings of guilt and depressive symptoms, 
which enhance and worsen OCD and negatively impact the 
response to treatment.
A study by Mataix-Cols et al investigated the degree of 
response to treatment using a series of clinical behavioral 
therapy trials in OCD outpatients. Patients with hoarding char-
acteristics seemed to have more difficulty than other patients 
in complying with behavioral therapy,116 and this finding is 
consistent with those of several studies. Hoarding patients 
often lack insight into their problems, are ego-syntonic 
with their behaviors, and do not recognize them as absurd, 
disabling, and time-consuming. Clinically, these patients are 
passive about treatment, endlessly delaying their homework 
assignments.117 Some studies on this issue have shown that 
these patients also respond less well to pharmacotherapy.112–118 
Thus, it seems important to develop specific programs for 
hoarders, with different cognitive behavioral interven-
tions, including training in decision-making, exposure and 
response prevention, and cognitive restructuring, together 
with appropriate pharmacological therapy targeted to reduce 
and downsize the burden of symptoms.126,127 Moreover, group 
treatment has been suggested to be superior to individual 
therapy in the management of hoarding behaviors, because 
sharing suffering and feeling part of a “common story” might 
enhance motivation for change.119
The course of obsessive-compulsive symptoms has a 
role in defining the response to treatment. A chronic course 
of disease is more likely in refractory patients, and has been 
demonstrated by some authors.120,121 In addition, chronic 
patients seem to have more severe symptoms from the outset, 
which can lead to worse impairment of emotional, social, and 
professional functioning, thus increasing the risk of a less 
favorable response to treatment.120
Identifying subgroups of OCD patients appears to be 
an important issue for understanding the pathophysiologi-
cal mechanisms of the disease better and developing more 
specialized treatment strategies. The OCD subtype called 
“with poor insight,” as defined in the Diagnostic and Statis-
tical Manual of Mental Disorders, Fourth Edition, includes 
subjects who do not recognize the excessiveness of their 
symptoms during the course of a current episode; the rate 
of this subtype varies from 15% to 36%, as showed in sev-
eral studies.122–124 Poor insight appears to be related to more 
severe OCD symptoms,122,123 early onset of the disease, and a 
longer duration of illness,123 and is a feature which frequently 
characterizes OCD patients with an associated schizotypal 
personality disorder.123,124 Moreover, overvalued obsessional 
beliefs have been shown to affect the response to individual 
and group therapy,125,126 perhaps due to lack of cognitive 
engagement by these patients. Instead, less homogenous 
results have been reported for the relationship between poor 
insight and response to medication; some researchers found 
a worse treatment response in this group of patients at both 
12 weeks and 6 months after an SSRI trial.113,122 A recent 
study by Catapano et al assessed the insight dimension in 
a group of OCD patients using a standardized instrument 
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called the Brown Assessment of Beliefs Scale, which covers 
a range of dimensions, such as beliefs, fixed ideas, insight, 
perception of others’ beliefs, and ideas of reference, aims to 
detect and focus on the patient’s dominant belief, concern, 
or delusion, and to estimate its impact on the patient’s life. 
The results obtained by Catapano et al showed significant 
impairment of critical skills in patients with poor insight, 
together with a strong and firm connection to their obsessive 
ideas and compulsive behaviors, experienced as right and 
unquestionable. Moreover, the poor insight group was char-
acterized by more severe symptomatology, an earlier onset 
of illness, and a higher rate of comorbidity with schizotypal 
personality disorder.127 This latter finding is in accordance 
with previous studies exploring this issue, and suggests an 
interaction between OCD and psychotic spectrum disorders. 
Some authors have hypothesized that OCD patients with 
poor insight and comorbid schizotypal personality may be 
considered as a separate subgroup with specific clinical 
features, worse treatment response rates and prognosis, and 
a close connection to schizophrenia-related disorders.124–128 
Paranoid ideation may affect a patient’s ability to understand 
fully the lack of sense in their obsessions and rituals, and it 
may also have bad implications in terms of treatment compli-
ance and response. On the other hand, SSRI therapy in OCD 
patients has been shown to ameliorate their insight, along 
with improvement in obsessive symptomatology. Accord-
ing to this finding, we might consider insight a dynamic 
phenomenon, affected by different variables, such as clinical 
condition, personality type, and affective status.124 In a study 
by Ravi Kishore et al, patients with poor insight were more 
likely to suffer from a depressive disorder, the insight score 
being closely correlated with this comorbidity.129 This find-
ing seems to be consistent with previous data showing high 
rates of depression among OCD patients with poor insight.131 
It has yet to be clarified whether depression contributes to 
poor insight or if it is more a consequence of a more severe 
form of the disease. Some authors have suggested that major 
depression might act on obsessions, transforming them into 
overvalued ideas which are difficult to criticize. From this 
perspective, improvement in depressive symptoms appears to 
be a necessary step towards achieving a positive outcome, in 
terms of clinical recovery and global functioning.131
The therapeutic implications for OCD patients with 
poor insight include lower rates of response, seen in both 
pharmacological trials and with psychotherapy. Accordingly, 
some authors have proposed that this subgroup of patients is 
  biologically different in terms of   neurotransmission   pathways, 
ie, these patients basically have a form of dopaminergic 
dysregulation.132 Clinicians have often treated these patients 
with antipsychotics in addition to SSRI, but to date no study 
has assessed whether insight predicts response to augmenta-
tion with antipsychotics in OCD. In the study by Catapano 
et al, they found that only 45% of OCD patients with poor 
insight showed a positive clinical outcome after the addition 
of low doses of neuroleptic to established SSRI therapy.127
Finally, an important issue that is closely related to a 
favorable course of OCD is family functioning. A change 
in family functioning due to a patient’s OCD behaviors may 
be seen in the so-called “family accommodation index.” It is 
very important to remind a patient’s relatives that performing 
rituals together with the patient or facilitating them reinforces 
the symptoms. Often, an overinvolved, frustrated, or rejecting 
attitude of family members increases the patient’s stress and 
worsens symptoms. There are some data showing that hostil-
ity, emotional overinvolvement, and criticism expressed by 
the family can be reflected in treatment outcomes, especially 
with cognitive behavioral therapy. Ferrao et al have provided 
evidence to support this notion, showing that OCD affecting 
family function is associated with a less favorable response 
to treatment, both pharmacological and psychotherapeutic.120 
Therefore, it seems important to pay attention to the patient’s 
family context in order to identify potential maladaptive 
behaviors which could affect the course of the disease, as well 
as the response to treatment. Social and family approaches 
have an essential therapeutic role, and should aim to affect 
the social, educational, and occupational functioning of the 
individual in a positive way.
Conclusion
Plenty of work has been done to improve the management 
of obsessive and phobic states. Despite the development of 
newer and safer treatment options, there are still a consider-
able number of patients who continue to bear a heavy burden 
of disability, silently accepting impairment in their quality of 
life, due to the insidious and chronic nature of these diseases. 
The first step towards a more effective therapeutic approach 
involves careful assessment of the symptoms expressed by 
the patient in order to make as precise a diagnosis as pos-
sible. Partial remission of symptoms and high relapse rates 
suggest the need to consider obsessive and phobic disorders 
in a dimensional rather than a categorical way, to identify 
patients’ real needs better, and then implement specific and 
patient-oriented treatment strategies. Reviewing current 
therapies in the management of these disorders has allowed us 
to think over some points. A change in the approach towards 
obsessive disease, considered as a spectrum of disorders, 
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provides a greater insight into its clinical expression, paying 
more attention to its psychopathological core, and the need to 
focus not only on the acute phase of the illness, but also on 
rehabilitation. The high degree of disability, which involves 
different aspects of patients’ lives, social isolation, together 
with psychiatric comorbidities, increase the burden of pain 
and anguish, so the aim of treatment should be achievement 
of global and long-lasting recovery in order to enable patients 
to achieve a better quality of life.
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